Could a daily aspirin save lives after pneumonia in the elderly?
NCT ID NCT06774846
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether taking a low-dose aspirin (100 mg) every day for 90 days can reduce deaths and heart-related complications in people aged 75 and older who are hospitalized with pneumonia. Researchers will compare aspirin against a placebo in 600 participants across multiple hospitals. The goal is to see if this simple, low-cost treatment can improve long-term survival after pneumonia.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Aspirin (acetylsalicylic acid) 100 mg daily
- What this could lead to
- If it works, this could offer a simple, cheap way to lower the risk of death and heart complications after pneumonia in older adults.
- What could go wrong
- This is a large phase 3 trial, but aspirin can cause bleeding, and the benefit may be small or absent. Results may not apply to all elderly patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 600 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
75 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Informed consent obtained from patient or relative/trusted person if patient unable to consent * Age ≥75 years * Clinical diagnosis of AP, presumed to be of bacterial or viral origin, with at least two of the following signs or symptoms: * cough, * purulent expectoration, * thoracic pain, * dyspnea/tachypnea, * temperature \> 37.8°C or \< 36°C, * unilateral crackles * Patient hospitalized for at least 48 hours * Onset of clinical signs \< 7 days * New radiological infiltrate documented by X-ray, ultrasound or CT scan Exclusion Criteria: * Mechanically ventilated pneumonia * Documented SARS CoV2 pneumonia * Patient with at least 3 episodes of inhalation pneumonitis in the 12 months prior to inclusion * Pre-acute episode swallowing disorders impairing oral medication intake * Physician-assessed life expectancy \< 90 days * Anticoagulant treatment (curative doses) * Antiplatelet therapy * Steroidal or non-steroidal anti-inflammatory treatment or oral corticosteroids without proton pump inhibitor (PPI) * Treatment with methotrexate (\>20 mg per week), anagrelide, probenecid, nicorandil, defibrotide * Dyspepsia or gastroesophageal reflux disease (GERD) without PPI use * Contraindications to aspirin (preventive doses) or its placebo at the time of inclusion: * Hypersensitivity to acetylsalicylic acid or to any of the excipients of the investigational drug or placebo * History of asthma induced by the administration of salicylates or non-steroidal anti-inflammatory drugs * Active peptic ulcer disease or history of recurrent peptic ulcer disease * History of cerebrovascular haemorrhage * Previous gastrointestinal hemorrhage * History of hemorrhage with Hemoglobin \> 3g /dl requiring transfusion, vasoactive treatment or surgery * Known hereditary or acquired coagulation disorder * Thrombocytopenia (platelets \< 50 giga/L) * Acute kidney injury (clairance \< 15 ml/min selon MDRD - Modification of Diet in Renal Disease), * Liver cirrhosis or acute liver failure (PTT\<50%), * Severe uncontrolled heart failure * Persistente severe hypertension (PAS \> 180mmHg) * Patient with mastocytosis * Person not affiliated to a national social security scheme * Patient under court protection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute pneumonia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.